Cas:6117-97-1 4-Methyldodecane manufacturer & supplier

We serve Chemical Name:4-Methyldodecane CAS:6117-97-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

4-Methyldodecane

Chemical Name:4-Methyldodecane
CAS.NO:6117-97-1
Synonyms:4-methyldodecane
Molecular Formula:C13H28
Molecular Weight:184.36100
HS Code:2901100000

Physical and Chemical Properties:
Melting point:N/A
Boiling point:102ºC / 14mmHg
Density:0.76
Index of Refraction:1.424
PSA:
Exact Mass:184.21900
LogP:5.17320

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 4-methyldodecane chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-methyldodecane physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-methyldodecane Use and application,4-methyldodecane technical grade,usp/ep/jp grade.


Related News: Catalent, a global leader in clinical supply services, recently announced the launch of its new CTSuccessTM clinical trial planning service, designed to support trial sponsors with earlier, more proactive and robust clinical supply chain planning, and reduce the risk of delays and budget overspend common to clinical trials as they progress. 4-Methyldodecane manufacturer Catalent, a global leader in clinical supply services, recently announced the launch of its new CTSuccessTM clinical trial planning service, designed to support trial sponsors with earlier, more proactive and robust clinical supply chain planning, and reduce the risk of delays and budget overspend common to clinical trials as they progress. 4-Methyldodecane supplier Zhejiang Huahai Pharmaceutical: It is a leading company in domestic APIs, especially in the field of cardiovascular drugs. 4-Methyldodecane vendor The GLOW trial doesn’t yet have the answer to that question, but Tendler pointed to encouraging early evidence from the regimen’s phase 2 trial, dubbed CAPTIVATE. Among eight patients who progressed after stopping the fixed-duration combo, six responded to subsequent Imbruvica monotherapy, while the other two didn’t have a response report, according to data presented at the recent American Society of Clinical Oncology annual meeting. 4-Methyldodecane factory Catalent, a global leader in clinical supply services, recently announced the launch of its new CTSuccessTM clinical trial planning service, designed to support trial sponsors with earlier, more proactive and robust clinical supply chain planning, and reduce the risk of delays and budget overspend common to clinical trials as they progress.